Seres Therapeutics Inc (NASDAQ:MCRB) has been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $18.25.

MCRB has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated a “buy” rating on shares of Seres Therapeutics in a report on Wednesday, August 30th. Seaport Global Securities restated a “buy” rating and set a $20.00 price target on shares of Seres Therapeutics in a report on Friday, October 6th. Cowen restated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Zacks Investment Research upgraded shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, December 5th. Finally, CIBC initiated coverage on shares of Seres Therapeutics in a report on Friday, October 13th. They set an “outperform” rating and a $19.00 price target on the stock.

Shares of Seres Therapeutics (NASDAQ:MCRB) opened at $10.47 on Thursday. Seres Therapeutics has a 1-year low of $8.85 and a 1-year high of $17.42. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.11.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.22. Seres Therapeutics had a negative net margin of 267.15% and a negative return on equity of 82.11%. The business had revenue of $23.00 million for the quarter, compared to analyst estimates of $17.29 million. During the same quarter in the previous year, the business earned ($0.46) earnings per share. The firm’s revenue was up 76.9% compared to the same quarter last year. equities research analysts expect that Seres Therapeutics will post -2.24 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC bought a new stake in Seres Therapeutics in the third quarter worth approximately $170,000. Perceptive Advisors LLC bought a new stake in Seres Therapeutics in the third quarter worth approximately $2,165,000. Schwab Charles Investment Management Inc. grew its position in Seres Therapeutics by 12.8% in the third quarter. Schwab Charles Investment Management Inc. now owns 103,286 shares of the biotechnology company’s stock worth $1,657,000 after acquiring an additional 11,743 shares in the last quarter. Schroder Investment Management Group bought a new stake in Seres Therapeutics in the third quarter worth approximately $1,088,000. Finally, JPMorgan Chase & Co. grew its position in Seres Therapeutics by 39.9% in the third quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock worth $6,160,000 after acquiring an additional 106,479 shares in the last quarter. 75.94% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: “Seres Therapeutics Inc (MCRB) Receives Consensus Recommendation of “Buy” from Brokerages” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/12/21/seres-therapeutics-inc-mcrb-receives-consensus-recommendation-of-buy-from-brokerages.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.